Company: IMCR
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001671927-25-000018
Chunk: 65

Company: Immunocore Holdings plc
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 65
---
. "Summary of significant accounting policies". The following table summarizes the reportable segment's financial information (in thousands):Three Months Ended September 30,Nine Months Ended September 30,2025202420252024Revenue$103,693 $80,248 $295,538 $226,150 Less:Cost of revenue from sale of therapies(513)(448)(2,384)(2,401)External research and development (R&D) expenses:PRAME programs(21,967)(18,512)(59,950)(67,144)Tebentafusp programs(11,789)(8,315)(30,196)(18,766)Infectious disease programs(1,347)(1,324)(4,077)(5,009)All other external clinical and preclinical costs(15,551)(6,361)(42,035)(17,309)Total external R&D expenses(50,654)(34,512)(136,258)(108,228)R&D salaries and other employee-related costs(11,932)(11,272)(35,882)(33,247)Selling, general and administrative (SG&A) salaries and other employee-related costs(14,038)(11,783)(39,083)(37,104)Other SG&A expenses(18,071)(19,009)(60,992)(56,801)Other segment (expense) income, net (a)(8,662)5,512 (26,393)(15,685)Segment and consolidated net (loss) income$(177)$8,736 $(5,454)$(27,316)(a) Other segment expenses, net includes other internal R&D expenses, share-based compensation expense, R&D tax credits, interest income, interest expense, foreign currency gain, other income, net and income tax expense (benefit).

14

10. Commitments and contingencies

Lease commitments The maturities of operating lease liabilities as of September 30, 2025 were as follows (in thousands):Remainder of 2025$1,451 20265,876 20275,786 20285,476 20295,205 2030 and thereafter48,949 Total lease payments72,743 Less imputed interest(29,468)Present value of operating lease liabilities$43,275 Future lease commitments - leases not yet commenced$2,973 Future lease commitments - leases not yet commencedThe